Article Details
Retrieved on: 2024-05-18 21:14:03
Tags for this article:
Click the tags to see associated articles and topics
Summary
Longeveron Inc., a leader in regenerative medicine, details progress in its Alzheimer's and hypoplastic left heart syndrome (HLHS) clinical trials, emphasizing the therapeutic promise of Lomecel-B. While addressing financial results, the company also highlights shifts in focus from Japan's Frailty trial to HLHS, indicating strategic reallocation.
Article found on: uk.investing.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here